Publication at Second Faculty of Medicine |
2014
Abstract
Denosumab, a human monoclonal antibody inhibiting ligand receptor activating nuclear factor kappa B (RANKL) is authorized for the treatment of osteoporosis and the prevention of skeletal events in patients with solid tumors. Integrated analysis registration study with 5723 patients, demonstrated delay the onset of the first SRE by 8.2 months compared with zoledronic acid.
